Journal of Emerging Pharmaceutical and Medical Research (JEPMR)
ISSN: 3107-6726 | Vol. 02, Issue-01, Jan-April. 2026 | pp. 61-74

Molecular Pharmacology of Ion Channels: Implications for Pain and Neurological Disorders

Priyanka Rani[1], Vinay Sagar Verma[1], Himanshu Mahato[1], Alok Tapan Pradhan[2], Gitanjali Kashyap[1*]

[1]Kamla Institute of Pharmaceutical Sciences, Junwani, Bhilai, Chhattisgarh, 490020.

[2]Danteshwari College of Pharmacy, Jagdalpur, Chhattisgarh, 494221.

***Corresponding Author E-mail: kashyapgitu216@gmail.com**

Abstract:

Ion channels are central to neuronal excitability and synaptic communication, tightly regulating the flow of sodium, potassium, calcium, and chloride ions across cellular membranes. Their dysfunction—arising from genetic mutations, post-translational modifications, or cellular stress—contributes to the pathogenesis of neuropathic pain, epilepsy, migraine, and other neurological disorders. This review delineates the major ion-channel families including voltage-gated sodium (NaV), calcium (CaV), and potassium (KV/HCN) channels, as well as transient receptor potential (TRP) and acid-sensing ion channels (ASICs), highlighting their molecular pharmacology and significance in pain and neurological pathophysiology. Mechanistic insights reveal that hyperexcitability, synaptic hypertransmission, and disinhibition resulting from altered ion-channel activity form the basis of chronic neuronal hyperactivity. The review further examines current pharmacological modulators—such as NaV1.8 inhibitors (VX-548), N-type calcium channel blockers (ziconotide), HCN inhibitors (ivabradine), and TRPV1 agonists (capsaicin)and their clinical implications. Despite promising advances, therapeutic translation is limited by issues of selectivity, delivery, and systemic safety. Emerging directions include structure-guided drug design, nanocarrier formulations, and genetically informed precision medicine. Collectively, ion-channel–targeted pharmacology embodies a shift from generalized symptom control toward highly specific, mechanism-based interventions for pain and neurological disorders.

Keywords: Ion Channels; Molecular Pharmacology; Neuropathic Pain; Voltage-Gated Sodium Channels; Calcium Channels; Potassium Channels; TRP Channels; Asics; Neuronal Excitability; Channelopathies; Analgesic Drug Development; Neurological Disorders; Precision Medicine; Ion-Channel Modulators

Received: Jan. 20, 2026 **Revised: Feb. 27, 2026** **Accepted: March. 28, 2026** **Published: April 12, 2026**

DOI: https://doi.org/10.64474/3107-6726.Vol2.Issue1.6

https://jepmr.nknpub.com/1/issue/archive

1. Introduction

Ion channels serve as the gatekeepers of electrical signalling in both neurons and glial cells, controlling the flow of key ions such as sodium (Na^+), potassium (K^+), calcium (Ca^{2+}), and chloride (Cl^-) across cellular membranes. These finely tuned molecular conduits regulate the generation and propagation of action potentials, synaptic transmission, and overall neuronal excitability [1]. When ion-channel function becomes disrupted—through genetic mutation, post-translational modification, or pathological stress—it can result in hyperexcitability, ectopic firing, and dysfunctional synaptic communication. Such alterations lie at the heart of neuropathic pain, epilepsy, migraine, and numerous other neurological disorders [2].

Historically, management of these disorders relied on broad-spectrum therapies such as opioids, anticonvulsants, and general anesthetics. While effective to some degree, these agents suffer from major limitations including tolerance, addiction potential, and systemic toxicity [3]. This has driven researchers to identify and develop more selective molecular targets. Ion channels, due to their discrete molecular architecture and subtype diversity, represent one of the most promising therapeutic frontiers. By modulating specific ion-channel subtypes, it becomes possible to precisely regulate neuronal signaling without widespread off-target effects [4-5].

This review explores the major ion-channel families—voltage-gated sodium, calcium, and potassium channels, as well as transient receptor potential (TRP) and acid-sensing ion channels (ASICs)—and discusses their pharmacological relevance in pain and neurological disorders. Additionally, it highlights current drug discovery efforts and future directions for ion-channel–targeted therapies [6].

2. Ion Channel Targets in Pain and Neurology

2.1 Voltage-Gated Sodium Channels (NaV):

Voltage-gated sodium channels are critical for initiating and propagating action potentials in excitable tissues. Specific subtypes such as NaV1.7, NaV1.8, and NaV1.9 are predominantly expressed in peripheral nociceptive neurons, where they regulate pain transmission [7]. Genetic studies have provided strong evidence of their importance—mutations in NaV1.7, for instance, can cause congenital insensitivity to pain or, conversely, lead to severe pain syndromes. Because of this, NaV channels have become a focal point for analgesic drug development, with selective inhibitors being explored as alternatives to opioids for chronic pain management [8].

2.3 Voltage-Gated Calcium Channels (CaV):

Calcium channels play dual roles in neuronal physiology: they influence membrane excitability and regulate the release of neurotransmitters at synapses. Among the various subtypes, N-type (CaV2.2) and T-type (CaV3.x) channels are closely linked with pain signaling and central sensitization. For example, overexpression of CaV3.2 in the anterior cingulate cortex has been correlated with neuropathic pain conditions. Pharmacological inhibition of these channels can reduce the release of excitatory

neurotransmitters such as glutamate and substance P, effectively dampening pain-related neuronal circuits and restoring normal excitability levels [9-10].

2.4 Voltage-Gated Potassium Channels (KV) and Hyperpolarization-Activated Channels (HCN):

Potassium channels function as stabilizers of the neuronal membrane potential by facilitating repolarization after an action potential. Dysregulation or downregulation of KV channels often leads to sustained depolarization and spontaneous firing, contributing to chronic pain and seizure disorders. Similarly, hyperpolarization-activated cyclic nucleotide-gated (HCN) channels regulate rhythmic neuronal activity and contribute to pacemaker potentials [11]. Modulating these channels—either by enhancing KV activity or suppressing HCN activity—offers potential strategies to normalize hyperexcitability in neuropathic and epileptic conditions.

2.5 Transient Receptor Potential (TRP) Channels:

The TRP channel family encompasses a diverse set of sensors that respond to physical and chemical stimuli such as heat, cold, and irritants. Subtypes like TRPV1, TRPA1, and TRPM8 play integral roles in the detection of thermal and chemical pain. TRPV1, known as the capsaicin receptor, is activated by noxious heat and inflammatory mediators, while TRPA1 responds to oxidative stress and environmental irritants [12]. Modulating TRP channels enables the interception of pain signals right at the transduction phase—before they can trigger central sensitization—making them valuable targets for developing peripherally acting analgesics.

2.6 Acid-Sensing Ion Channels (ASICs):

ASICs are proton-gated channels that sense extracellular acidity, which typically arises during inflammation, ischemia, or tissue injury. Subtypes such as ASIC1A and ASIC3 are found in sensory neurons and central pathways, where their activation contributes to pain hypersensitivity and neurodegeneration. Inhibiting these channels has shown promise in alleviating inflammatory and ischemic pain, as well as in mitigating excitotoxic neuronal injury [13].

3.Mechanistic Insights and Pathophysiology

Ion-channel dysfunction plays a fundamental role in the pathogenesis of pain and neurological disorders, acting through a network of interconnected mechanisms that alter neuronal excitability and synaptic signaling. One of the most prominent mechanisms is hyperexcitability of nociceptors, where upregulation or gain-of-function mutations in sodium channel subtypes such as NaV1.7 and NaV1.8 enhance the initiation and propagation of action potentials. This abnormal increase in spontaneous or ectopic firing contributes to persistent pain perception even in the absence of peripheral stimuli [14].A second key mechanism involves synaptic hypertransmission, primarily driven by enhanced calcium channel activity, particularly through CaV2.2 channels. The increased calcium influx at presynaptic terminals facilitates excessive

release of excitatory neurotransmitters like glutamate in the dorsal horn and trigeminal pathways, resulting in central sensitization and amplification of pain signaling within the spinal cord and brainstem [15].

Another contributing factor is the reduction of inhibitory currents. When the function or expression of potassium channels (KV) or hyperpolarization-activated cyclic nucleotide-gated channels (HCN) is downregulated, the normal inhibitory brakes on neuronal firing are removed. This disinhibition fosters sustained depolarization and repetitive firing, creating a state of uncontrolled neuronal activity often seen in chronic pain and seizure disorders [16]. Peripheral sensitization also plays a pivotal role. (Figure 1**)** Activation of TRP and ASIC channels increases the sensitivity of sensory neurons to mechanical, thermal, and chemical stimuli. These channels act as molecular detectors of tissue damage and inflammation, and their heightened responsiveness leads to exaggerated pain perception in conditions such as arthritis, tissue injury, and migraine [17].

Figure 1 illustrates the sequence from peripheral ion-channel activation to central sensitization.



4. Pharmacological Modulators of Ion Channels

The pharmacological modulation of ion channels represents one of the most promising strategies for managing chronic pain and neurological disorders. Ion channels serve as precise molecular targets due to their structural specificity and distinct expression patterns across tissues, allowing for the design of selective modulators that fine-tune neuronal excitability [18]. Despite significant advances in identifying subtype-selective ligands, translating these discoveries into effective clinical therapies remains a challenge. Issues such as subtype redundancy, off-target toxicity, and restricted tissue penetration continue to limit therapeutic success, making this an active and evolving field of research [19].

4.1 Sodium Channel Modulators

Selective inhibitors of voltage-gated sodium channels—particularly NaV1.7 and NaV1.8—have drawn significant attention as next-generation analgesics. Compounds such as A-803467 and A-887826 demonstrate over 100-fold selectivity for NaV1.8 and have shown robust efficacy in reducing neuropathic pain in animal models [20]. Recently, VX-548 (suzetrigine) received FDA approval for the management of moderate-to-severe acute pain and is currently being explored for its application in neuropathic pain syndromes. However, translating these findings into long-term clinical success remains difficult. Limited penetration of these drugs into peripheral nerves, functional overlap among sodium channel subtypes, and risks of off-target side effects have posed considerable hurdles. Consequently, sodium channel modulation continues to be an active frontier of drug discovery in pain research [21].

4.2 Calcium Channel Modulators

Voltage-gated calcium channels are essential regulators of neuronal excitability and neurotransmitter release, making them critical pharmacological targets. Ziconotide, a synthetic peptide derived from cone snail venom that blocks N-type (CaV2.2) channels, is approved for treating severe chronic pain via intrathecal administration. T-type calcium channel inhibitors targeting CaV3.x subtypes have also demonstrated analgesic efficacy in preclinical models—for instance, silencing CaV3.2 expression in the anterior cingulate cortex reduces neuropathic pain responses [22]. Despite these promising findings, challenges persist. The need for invasive delivery routes, narrow therapeutic windows, and dose-limiting side effects—particularly those involving motor and cognitive function—restrict the broader clinical use of calcium channel blockers.

4.3 Potassium and HCN Channel Modulators

Potassium (KV) channels and hyperpolarization-activated cyclic nucleotide-gated (HCN) channels act as stabilizing forces that maintain neuronal resting potential and limit excessive firing. Enhancing the activity of potassium channels or inhibiting HCN channels can help reestablish the balance between excitation and inhibition disrupted in neuropathic pain [23]. Although this area has received less research attention than sodium or calcium channels, it holds notable therapeutic promise. Ivabradine, an HCN channel blocker primarily used for cardiac conditions, has shown analgesic effects in experimental human pain models involving capsaicin-induced hyperalgesia. Similarly, pharmacological activation of potassium channels may counteract hyperexcitability in neurons, presenting a novel strategy for alleviating chronic pain and seizure disorders [24].

4.4 TRP and ASIC Channel Modulators

Transient receptor potential (TRP) and acid-sensing ion channel (ASIC) modulators represent emerging strategies for peripheral pain control. High-dose topical capsaicin, a TRPV1 agonist that induces desensitization through prolonged activation, is already in clinical use for neuropathic pain conditions such as postherpetic neuralgia. Beyond TRPV1, other TRP subtypes like TRPA1, TRPM3, and TRPM8 are under investigation for their roles in detecting noxious stimuli and mediating inflammatory pain. ASIC channel inhibitors, designed to block acid-induced pain signaling during inflammation or ischemia, are in early experimental stages [25]. However, the clinical progression of TRP antagonists has been slowed by issues such as thermoregulatory disturbances and inconsistent analgesic outcomes in human trials. Despite these obstacles, continued optimization of TRP and ASIC modulators holds significant potential for developing effective non-opioid analgesics [26].

Table 1: Pharmacological Modulators of Ion Channels

Target / Channel Family	Drug / Compound	Mechanism of Action	Therapeutic Indications	Reference
NaV channels (e.g., NaV1.8)	A-803467, A-887826	Selective NaV1.8 blocker	Neuropathic pain	27
NaV channels	VX-548 (suzetrigine)	NaV1.8 selective inhibition	Acute pain (studied for neuropathic)	28
CaV channels (CaV2.2)	Ziconotide	N-type Ca^{2+} channel blocker	Severe chronic neuropathic pain (intrathecal)	29
CaV channels (CaV3.x)	T-type inhibitors	T-type Ca^{2+} channel blockade	Neuropathic/inflammatory pain	30
KV / HCN channels	Ivabradine (HCN blocker)	HCN channel inhibition	Experimental human pain model	31

TRP channels (e.g., TRPV1)	High-dose capsaicin patches	TRPV1 agonist → desensitisation	Neuropathic pain	32
ASIC channels	Emerging inhibitors	ASIC blockade (acid-sensing)	Pain & neuro disorders under investigation	33

5. Applications in Neurological Disorders

Beyond pain syndromes, ion-channel modulation plays a vital role across a wide range of neurological disorders. Ion channels are deeply integrated into the regulation of neuronal excitability, synaptic transmission, and neuroinflammatory responses—making them valuable therapeutic targets in conditions such as migraine, epilepsy, and multiple sclerosis [34].Migraine is one of the most well-established channelopathies, characterized by dysregulation of ion channels within trigeminal sensory pathways. Channels such as CaV2.1, HCN, and NaV1.1 are implicated in cortical spreading depolarization and trigeminovascular activation—key events driving migraine aura and pain phases. The modulation of these channels can attenuate neuronal hyperexcitability and reduce migraine frequency and severity [35].

In epilepsy, alterations in sodium, potassium, calcium, and HCN channels contribute to the hyper-synchronous firing of neuronal networks, which underlie seizure generation. Many conventional antiepileptic drugs—such as carbamazepine, valproate, and lamotrigine—act by stabilizing ion-channel function to dampen neuronal excitability. Current research continues to explore subtype-selective modulators to achieve more precise control with fewer cognitive and motor side effects [36].

In multiple sclerosis and other neuroinflammatory disorders, ion channels are essential mediators of glial cell activation and inflammatory signaling. For instance, the TRPM2 channel in microglia contributes to reactive oxygen species (ROS)–mediated neurotoxicity and demyelination. Inhibiting such channels may help limit secondary neuronal damage and neuroinflammation [37].

6. Future Therapeutic Directions

The future of ion-channel–based therapeutics lies in refining selectivity, improving drug design, and embracing integrative approaches that combine molecular precision with clinical applicability.

Improved Selectivity**:** One of the central challenges in ion-channel drug development is achieving high subtype specificity (Figure 3). For example, distinguishing between NaV1.7 (a pain-related subtype) and NaV1.5 (a cardiac subtype) is critical to avoid cardiotoxicity. Advances in structure-guided drug design, cryo-EM studies, and molecular modeling are enabling the creation of compounds with superior selectivity and safety profiles [38-39].

Enhanced Bioavailability and Safety: Many promising ion-channel modulators suffer from limited oral bioavailability or require invasive routes of administration, such as intrathecal delivery. Additionally, dose-dependent adverse effects—such as sedation, motor impairment, or cardiovascular disturbances—continue to limit therapeutic windows. Future strategies will focus on developing allosteric modulators, nanocarrier formulations, and brain-penetrant molecules that retain efficacy while minimizing systemic toxicity [40].

Combination Therapy: A single-agent approach is often insufficient in complex neurological disorders. Combining ion-channel modulators with biologics, anti-inflammatory agents, or epigenetic regulators may enhance therapeutic efficacy and allow for lower, safer dosing regimens. Such multimodal approaches are gaining traction as part of precision pain management strategies [41].

Precision Medicine and Genetic Insights: With the growing understanding of genetic channelopathies, such as NaV1.7 mutations in inherited pain disorders, it is becoming possible to stratify patients based on genetic profiles and tailor channel-targeted therapies accordingly. Personalized ion-channel modulation could revolutionize pain and neurological treatment paradigms [42].

Natural Products and Allosteric Modulators: Natural compounds continue to serve as invaluable scaffolds for novel ion-channel modulators. Many plant- and marine-derived compounds exhibit allosteric or voltage-dependent modulation of ion-channel function, offering opportunities for developing safer and more effective agents with unique mechanisms of action [43].

Emerging Targets: Mechanosensitive ion channels like PIEZO1 and PIEZO2, as well as intracellular modulators such as the TRPM2/ROS axis, are gaining increasing research interest. These channels represent underexplored but highly relevant targets in neuropathic pain, ischemic injury, and neurodegeneration (Figure 2). Expanding the pharmacological landscape to include such emerging pathways could usher in a new era of precision neurotherapeutics. In conclusion, the evolution of ion-channel pharmacology reflects a paradigm shift from broad-acting analgesics to selective, mechanism-based therapies [44]. Continued integration of structural biology, computational modeling, and molecular pharmacology will be essential to translate these discoveries into safe, effective, and personalized treatments for pain and neurological disorders.

Figure 2: Emerging pharmacological strategy map for ion-channel modulation in pain and neurological disorders (selective blockers, allosteric modulators, natural products, combination therapy)



Figure 3: Structural representations of major ion-channels (NaV1.7, CaV2.2, TRPV1) annotated with drug-binding sites and modulatory mechanisms.



8. Conclusion

Ion channels lie at the heart of neuronal excitability, and their dysregulation underpins a wide spectrum of pain and neurological disorders. The molecular pharmacology of these channels offers a pathway away from non-specific therapies and toward precision, mechanism-based

interventions. While challenges remain—selectivity, safety, penetration into nervous tissue—the continuing advances in structural biology, channelopathy genetics, and pharmacology herald a new era. Ion-channel modulation may soon transition from niche therapy to mainstream clinical strategy in pain and neurology.

References

1. Finnerup, N. B., Kuner, R., & Jensen, T. S. (2021). Neuropathic pain: From mechanisms to treatment. *Physiological Reviews, 101*(1), 259–301. https://doi.org/10.1152/physrev.00045.2019
2. van Hecke, O., Austin, S. K., Khan, R. A., Smith, B. H., & Torrance, N. (2014). Neuropathic pain in the general population: A systematic review of epidemiological studies. *Pain, 155*(4), 654–662. https://doi.org/10.1016/j.pain.2013.11.013
3. Colloca, L., Ludman, T., Bouhassira, D., Baron, R., Dickenson, A. H., Yarnitsky, D., Freeman, R., Truini, A., Attal, N., Finnerup, N. B., et al. (2017). Neuropathic pain. *Nature Reviews Disease Primers, 3*, 17002. https://doi.org/10.1038/nrdp.2017.2
4. St John Smith, E. (2018). Advances in understanding nociception and neuropathic pain. *Journal of Neurology, 265*(2), 231–238. https://doi.org/10.1007/s00415-017-8641-6
5. Bagal, S. K., Marron, B. E., Owen, R. M., Storer, R. I., & Swain, N. A. (2015). Voltage-gated sodium channels as drug discovery targets. *Channels, 9*(6), 360–366. https://doi.org/10.1080/19336950.2015.1079674
6. Catterall, W. A., Lenaeus, M. J., & Gamal El-Din, T. M. (2020). Structure and pharmacology of voltage-gated sodium and calcium channels. *Annual Review of Pharmacology and Toxicology, 60*, 133–154. https://doi.org/10.1146/annurev-pharmtox-010818-021757
7. Catterall, W. A. (2023). Voltage-gated sodium and calcium channels: Discovery, structure, function, and pharmacology. *Channels, 17*(1), 2281714. https://doi.org/10.1080/19336950.2023.2281714
8. Namadurai, S., Yereddi, N. R., Cusdin, F. S., Huang, C. L., Chirgadze, D. Y., & Jackson, A. P. (2015). A new look at sodium channel β subunits. *Open Biology, 5*(1), 140192. https://doi.org/10.1098/rsob.140192
9. O'Malley, H. A., & Isom, L. L. (2015). Sodium channel β subunits: Emerging targets in channelopathies. *Annual Review of Physiology, 77*, 481–504. https://doi.org/10.1146/annurev-physiol-021014-071846
10. Chahine, M., & O'Leary, M. E. (2011). Regulatory role of voltage-gated Na channel β subunits in sensory neurons. *Frontiers in Pharmacology, 2*, 70. https://doi.org/10.3389/fphar.2011.00070
11. Cox, J. J., Reimann, F., Nicholas, A. K., Thornton, G., Roberts, E., Springell, K., Karbani, G., Jafri, H., Mannan, J., Raashid, Y., et al. (2006). An SCN9A channelopathy causes congenital inability to experience pain. *Nature, 444*(7121), 894–898. https://doi.org/10.1038/nature05413

12. Lampert, A., O'Reilly, A. O., Reeh, P., & Leffler, A. (2010). Sodium channelopathies and pain. *Pflügers Archiv - European Journal of Physiology, 460*(2), 249–263. https://doi.org/10.1007/s00424-010-0810-3
13. Goodwin, G., & McMahon, S. B. (2021). The physiological function of different voltage-gated sodium channels in pain. *Nature Reviews Neuroscience, 22*(5), 263–274. https://doi.org/10.1038/s41583-021-00441-2
14. Bennett, D. L. H., Clark, A. J., Huang, J., Waxman, S. G., & Dib-Hajj, S. D. (2019). The role of voltage-gated sodium channels in pain signaling. *Physiological Reviews, 99*(2), 1079–1151. https://doi.org/10.1152/physrev.00052.2017
15. Comini, M., Themistocleous, A. C., & Bennett, D. L. H. (2024). Human pain channelopathies. *Handbook of Clinical Neurology, 203*, 89–109. https://doi.org/10.1016/B978-0-323-99701-6.00009-7
16. Zhang, J. M., Donnelly, D. F., Song, X. J., & Lamotte, R. H. (1997). Axotomy increases the excitability of dorsal root ganglion cells with unmyelinated axons. *Journal of Neurophysiology, 78*(5), 2790–2794. https://doi.org/10.1152/jn.1997.78.5.2790
17. Devor, M. (2006). Sodium channels and mechanisms of neuropathic pain. *The Journal of Pain, 7*(Suppl. 1), S3–S12. https://doi.org/10.1016/j.jpain.2005.09.006
18. Liu, C. N., Michaelis, M., Amir, R., & Devor, M. (2000). Spinal nerve injury enhances subthreshold membrane potential oscillations in DRG neurons: Relation to neuropathic pain. *Journal of Neurophysiology, 84*(1), 205–215. https://doi.org/10.1152/jn.2000.84.1.205
19. Amir, R., Michaelis, M., & Devor, M. (2002). Burst discharge in primary sensory neurons: Triggered by subthreshold oscillations, maintained by depolarizing afterpotentials. *Journal of Neuroscience, 22*(4), 1187–1198. https://doi.org/10.1523/JNEUROSCI.22-04-01187.2002
20. Gold, M. S., Weinreich, D., Kim, C. S., Wang, R., Treanor, J., Porreca, F., & Lai, J. (2003). Redistribution of NaV1.8 in uninjured axons enables neuropathic pain. *Journal of Neuroscience, 23*(5), 158–166. https://doi.org/10.1523/JNEUROSCI.23-05-00158.2003
21. Gracely, R. H., Lynch, S. A., & Bennett, G. J. (1992). Painful neuropathy: Altered central processing maintained dynamically by peripheral input. *Pain, 51*(2), 175–194. https://doi.org/10.1016/0304-3959(92)90260-F
22. Bao, L. (2015). Trafficking regulates the subcellular distribution of voltage-gated sodium channels in primary sensory neurons. *Molecular Pain, 11*, 61. https://doi.org/10.1186/s12990-015-0061-7
23. Hameed, S. (2019). NaV1.7 and NaV1.8: Role in the pathophysiology of pain. *Molecular Pain, 15*, 1744806919858801. https://doi.org/10.1177/1744806919858801
24. Dib-Hajj, S. D., Black, J. A., & Waxman, S. G. (2009). Voltage-gated sodium channels: Therapeutic targets for pain. *Pain Medicine, 10*(7), 1260–1269. https://doi.org/10.1111/j.1526-4637.2009.00696.x

25. Sleeper, A. A., Cummins, T. R., Dib-Hajj, S. D., Hormuzdiar, W., Tyrrell, L., Waxman, S. G., & Black, J. A. (2000). Changes in expression of two tetrodotoxin-resistant sodium channels and their currents in dorsal root neurons after sciatic nerve injury but not rhizotomy. *Journal of Neuroscience, 20*(19), 7279–7289. https://doi.org/10.1523/JNEUROSCI.20-19-07279.2000
26. Yin, R., Liu, D., Chhoa, M., Li, C. M., Luo, Y., Zhang, M., Lehto, S. G., Immke, D. C., & Moyer, B. D. (2016). Voltage-gated sodium channel function and expression in injured and uninjured rat dorsal root ganglia neurons. *International Journal of Neuroscience, 126*(2), 182–192. https://doi.org/10.3109/00207454.2015.1019563
27. Dib-Hajj, S. D., Black, J. A., & Waxman, S. G. (2015). NaV1.9: A sodium channel linked to human pain. *Nature Reviews Neuroscience, 16*(9), 511–519. https://doi.org/10.1038/nrn3977
28. Pineda-Farias, J. B., Loeza-Alcocer, E., Nagarajan, V., Gold, M. S., & Sekula, R. F., Jr. (2021). Mechanisms underlying the selective therapeutic efficacy of carbamazepine for attenuation of trigeminal nerve injury pain. *Journal of Neuroscience, 41*(43), 8991–9007. https://doi.org/10.1523/JNEUROSCI.0720-21.2021
29. Wang, W., Atianjoh, F., Gauda, E. B., Yaster, M., Li, Y., & Tao, Y. X. (2011). Increased expression of sodium channel subunit NaV1.1 in the injured dorsal root ganglion after peripheral nerve injury. *The Anatomical Record, 294*(8), 1406–1411. https://doi.org/10.1002/ar.21398
30. Cummins, T. R., & Waxman, S. G. (1997). Downregulation of tetrodotoxin-resistant sodium currents and upregulation of a rapidly repriming tetrodotoxin-sensitive sodium current in small spinal sensory neurons after nerve injury. *Journal of Neuroscience, 17*(9), 3503–3514. https://doi.org/10.1523/JNEUROSCI.17-09-03503.1997
31. Waxman, S. G., Kocsis, J. D., & Black, J. A. (1994). Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons and is reexpressed following axotomy. *Journal of Neurophysiology, 72*(1), 466–470. https://doi.org/10.1152/jn.1994.72.1.466
32. Lai, J., Porreca, F., Hunter, J. C., & Gold, M. S. (2004). Voltage-gated sodium channels and hyperalgesia. *Annual Review of Pharmacology and Toxicology, 44*, 371–397. https://doi.org/10.1146/annurev.pharmtox.44.101802.121627
33. Blackburn-Munro, G., & Fleetwood-Walker, S. M. (1999). The sodium channel auxiliary subunits beta1 and β2 are differentially expressed in the spinal cord of neuropathic rats. *Neuroscience, 90*(1), 153–164. https://doi.org/10.1016/S0306-4522(98)00432-9
34. Calhoun, J. D., & Isom, L. L. (2014). The role of non-pore-forming β subunits in physiology and pathophysiology of voltage-gated sodium channels. *Handbook of Experimental Pharmacology, 221*, 51–89. https://doi.org/10.1007/978-3-642-41588-3_3

35. Pertin, M., Ji, R. R., Berta, T., Powell, A. J., Karchewski, L., Tate, S. N., Isom, L. L., Woolf, C. J., Gilliard, N., Spahn, D. R., & others. (2005). Upregulation of the voltage-gated sodium channel β2 subunit in neuropathic pain models: Characterization of expression in injured and non-injured primary sensory neurons. *Journal of Neuroscience, 25*(46), 10970–10980. https://doi.org/10.1523/JNEUROSCI.2617-05.2005
36. Lopez-Santiago, L. F., Pertin, M., Morisod, X., Chen, C., Hong, S., Wiley, J., Decosterd, I., & Isom, L. L. (2006). Sodium channel β2 subunits regulate tetrodotoxin-sensitive sodium channels in small dorsal root ganglion neurons and modulate the response to pain. *Journal of Neuroscience, 26*(31), 7984–7994. https://doi.org/10.1523/JNEUROSCI.0948-06.2006
37. Shah, B. S., Stevens, E. B., Gonzalez, M. I., Bramwell, S., Pinnock, R. D., Lee, K., & Dixon, A. K. (2000). β3, a novel auxiliary subunit for the voltage-gated sodium channel, is expressed preferentially in sensory neurons and is upregulated in the chronic constriction injury model of neuropathic pain. *European Journal of Neuroscience, 12*(10), 3985–3990. https://doi.org/10.1046/j.1460-9568.2000.00295.x
38. Takahashi, N., Kikuchi, S., Dai, Y., Kobayashi, K., Fukuoka, T., & Noguchi, K. (2003). Expression of auxiliary β subunits of sodium channels in primary afferent neurons and the effect of nerve injury. *Neuroscience, 121*(2), 441–450. https://doi.org/10.1016/S0306-4522(03)00480-2
39. Cummins, T. R., Aglieco, F., Renganathan, M., Herzog, R. I., Dib-Hajj, S. D., & Waxman, S. G. (2001). NaV1.3 sodium channels: Rapid repriming and slow closed-state inactivation display quantitative differences after expression in a mammalian cell line and in spinal sensory neurons. *Journal of Neuroscience, 21*(16), 5952–5961. https://doi.org/10.1523/JNEUROSCI.21-16-05952.2001
40. Fukuoka, T., Kobayashi, K., Yamanaka, H., Obata, K., Dai, Y., & Noguchi, K. (2008). Comparative study of the distribution of the α-subunits of voltage-gated sodium channels in normal and axotomized rat dorsal root ganglion neurons. *Journal of Comparative Neurology, 510*(2), 188–206. https://doi.org/10.1002/cne.21787
41. Zhao, J., O'Leary, M. E., & Chahine, M. (2011). Regulation of NaV1.6 and NaV1.8 peripheral nerve Na+ channels by auxiliary β-subunits. *Journal of Neurophysiology, 106*(2), 608–619. https://doi.org/10.1152/jn.00074.2011
42. Chen, C., Westenbroek, R. E., Xu, X., Edwards, C. A., Sorenson, D. R., Chen, Y., McEwen, D. P., O'Malley, H. A., Bharucha, V., Meadows, L. S., & others. (2004). Mice lacking sodium channel beta1 subunits display defects in neuronal excitability, sodium channel expression, and nodal architecture. *Journal of Neuroscience, 24*(16), 4030–4042. https://doi.org/10.1523/JNEUROSCI.4714-03.2004
43. Lopez-Santiago, L. F., Brackenbury, W. J., Chen, C., & Isom, L. L. (2011). Na^+ channel *Scn1b* gene regulates dorsal root ganglion nociceptor excitability *in vivo*. *Journal of*

Biological Chemistry, 286(26), 22913–22923. https://doi.org/10.1074/jbc.M110.201343

44. Ma, R. S. Y., Kayani, K., Whyte-Oshodi, D., Whyte-Oshodi, A., Nachiappan, N., Gnanarajah, S., & Mohammed, R. (2019). Voltage-gated sodium channels as therapeutic targets for chronic pain. *Journal of Pain Research, 12*, 2709–2722. https://doi.org/10.2147/JPR.S207720